 |
FOR IMMEDIATE RELEASE
Contact:
Dana Thomas
Trinity Biotech USA
908.898.1500 x7010
|
Contact:
Diane Lewis
Media Director
GráficaGroup
908.879.2169 x173
|
TRINITY BIOTECH NAMES GRÁFICAGROUP AGENCY OF RECORD
Gráfica supporting clinical diagnostic instrumentation marketing in hemostasis, immunodiagnostics, and rapid HIV testing
Chester, New Jersey (June 21, 2005) — Today, GráficaGroup officially announced that Trinity Biotech USA has named the Chester-based company as its new Agency of Record. After reviewing several agencies in the first quarter of 2005, Trinity selected Gráfica to help develop and communicate a new brand position to support an overall marketing-communications campaign. Gráfica will provide advertising, media, trade-show support, and interactive services for Trinity, as the company continues its growth and expansion within multiple clinical diagnostic markets, including hemostasis, immunodiagnostics, specialty chemistry, and rapid HIV testing.
"After establishing our U.S. headquarters in New Jersey this year, we sought an agency that could help position the Trinity brand and tell the Trinity story to our key markets," said Philippe Gadal, Ph.D., U.S. CEO, Trinity Biotech. "Gráfica proved they possess the requisite creative talent and branding experience that Trinity needs to effectively promote our products, technology, and service, as we continue growing business and market share in the United States."
Gráfica began its relationship with Trinity by developing a new brand position, print advertisement, and tagline: Diagnostics Driven by Life®. The campaign starts in June in several publications targeting clinical diagnostic professionals and public health officials. The new Trinity campaign conveys how Trinity understands the pressures of life in the laboratory, while communicating the well-known brands in the company's portfolio, which includes AMAX Destiny™ (coagulation), NEXGEN Four (infectious disease), and the Uni-Gold™ Recombigen® rapid HIV test.
"Trinity's products greatly improve the way diagnostic laboratories function, and its Uni-Gold product is the fastest and simplest test for detecting HIV infection," said Debra Taeschler, President and CEO, GráficaGroup. "We at Gráfica look forward to integrating the brand position we developed for Trinity across multiple media, including the Web, which we believe will help Trinity assume market leadership in hemostasis, infectious disease, clinical chemistry, and rapid HIV testing."
About Trinity Biotech USA
With its U.S. Corporate Headquarters based in Berkeley Heights, New Jersey, Trinity Biotech Inc. is a wholly owned subsidiary of Trinity Biotech plc (NASDAQ: TRIB). With World Headquarters in Bray, Ireland, Trinity Biotech plc was established in 1992. Through an acquisition-growth strategy, Trinity has acquired companies with expertise in the development and commercialization of both instrumentation and reagents primarily servicing the infectious disease, hemostasis, specialty chemistry, and HIV diagnostics markets. Additional information about Trinity is available on the company Web site at www.trinitybiotech.com
Forward-Looking Statements
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
|
